Vatska Medtech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-07-2024
- Paid Up Capital ₹ 0.10 M
as on 26-07-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.30 Cr
as on 26-07-2024
- Revenue 24.70%
(FY 2023)
- Profit -26.62%
(FY 2023)
- Ebitda -1.29%
(FY 2023)
- Net Worth 22.00%
(FY 2023)
- Total Assets 73.85%
(FY 2023)
About Vatska Medtech
The Corporate was formerly known as Instas Life Science Consultancy Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.30 Cr.
Ramadas Ramasubramanian, Venkatram Bakthavatchalam, and Shanmathi serve as directors at the Company.
- CIN/LLPIN
U74120TN2014PTC167162
- Company No.
079569
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Maduravoyal, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Vatska Medtech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramadas Ramasubramanian  | Additional Director | 16-Mar-2021 | Current |
| Venkatram Bakthavatchalam | Director | 23-May-2014 | Current |
| Shanmathi | Director | 17-Sep-2020 | Current |
Financial Performance of Vatska Medtech.
Vatska Medtech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 24.7% increase. The company also saw a substantial fall in profitability, with a 26.62% decrease in profit. The company's net worth Soared by an impressive increase of 22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vatska Medtech?
In 2023, Vatska Medtech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Igl India Transplantation Solutions Private LimitedActive 4 years 10 monthsVenkatram Bakthavatchalam is a mutual person
- Aravindha Medical Innovations LlpActive 3 years 5 months
Venkatram Bakthavatchalam is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Mar 2024 | ₹2.30 Cr | Open |
How Many Employees Work at Vatska Medtech?
Unlock and access historical data on people associated with Vatska Medtech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vatska Medtech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vatska Medtech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
